Ang II and Ang IV: Unraveling the mechanism of action on synaptic plasticity, memory, and epilepsy

CNS Neuroscience and Therapeutics

Volumn 14, Issue 4, 2008, Pages 315-339

  De Bundel, Dimitri ^a   Smolders, Ilse ^a   Vanderheyden, Patrick ^a   Michotte, Yvette ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Angiotensin system; AT4 receptor; c MET; Epilepsy; IRAP; LTD; LTP; Memory

Indexed keywords

AMINOPEPTIDASE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 4 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN II [3-8]; ANGIOTENSIN IV [1 NORLEUCINAL]; ANGIOTENSIN IV [1 NORLEUCINE]; DIVALINAL ANGIOTENSIN IV; INSULIN REGULATED AMINOPEPTIDASE; LEUCYLVALYLVALINE HEMORPHIN 7; LIGAND; RECEPTOR SUBTYPE; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANTICONVULSANT ACTIVITY; BRAIN REGION; COGNITIVE DEFECT; DENTATE GYRUS; DRUG BINDING SITE; DRUG RECEPTOR BINDING; EPILEPSY; EPISODIC MEMORY; FACILITATION; HIPPOCAMPUS; HUMAN; LEARNING; LONG TERM MEMORY; LONG TERM POTENTIATION; MEMORY; NERVE CELL PLASTICITY; NONHUMAN; PASSIVE AVOIDANCE; RECEPTOR AFFINITY; RECEPTOR UPREGULATION; REVIEW; SPATIAL MEMORY; SYNAPTIC TRANSMISSION;

ANGIOTENSIN II; ANIMALS; AVOIDANCE LEARNING; BINDING SITES; EPILEPSY; HUMANS; MEMORY; NEURONAL PLASTICITY; RECEPTORS, ANGIOTENSIN; SYNAPSES;

EID: 56049111427     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2008.00057.x     Document Type: Review

References (267)

1. Wright JW, Yamamoto BJ, Harding JW. Angiotensin receptor subtype mediated physiologies and behaviors: New discoveries and clinical targets. Prog Neurobiol 2008 84 : 157 181.
2. de Gasparo M, Hess P, Nuesslein-Hildesheim B, Bruneval P, Clozel JP. Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction. J Renin Angiotensin Aldosterone Syst 2000 1 : 151 158.
3. Wright JW, Miller-Wing AV, Shaffer MJ, Higginson C, Wright DE, Hanesworth JM, Harding JW. Angiotensin II(3-8) (ANG IV) hippocampal binding: potential role in the facilitation of memory. Brain Res Bull 1993 32 : 497 502.
4. Yang R, Smolders I, De Bundel D, Fouyn R, Halberg M, Demaegdt H, Vanderheyden P, Dupont AG. Brain and peripheral angiotensin II type 1 receptors mediate renal vasoconstrictor and blood pressure responses to angiotensin IV in the rat. J Hypertens 2008 26 : 998 1007.
5. Wisniewski K, Borawska M, Car H. The effect of angiotensin II and its fragments on post-alcohol impairment of learning and memory. Pol J Pharmacol 1993 45 : 23 29.
6. Wright JW, Clemens JA, Panetta JA, Smalstig EB, Weatherly LA, Kramar EA, Pederson ES, Mungall BH, Harding JW. Effects of LY231617 and angiotensin IV on ischemia-induced deficits in circular water maze and passive avoidance performance in rats. Brain Res 1996 717 : 1 11.
7. Wright JW, Stubley L, Pederson ES, Kramar EA, Hanesworth JM, Harding JW. Contributions of the brain angiotensin IV-AT4 receptor subtype system to spatial learning. J Neurosci 1999 19 : 3952 3961.
8. Pederson ES, Harding JW, Wright JW. Attenuation of scopolamine-induced spatial learning impairments by an angiotensin IV analog. Regul Pept 1998 74 : 97 103.
9. Pederson ES, Krishnan R, Harding JW, Wright JW. A role for the angiotensin AT4 receptor subtype in overcoming scopolamine-induced spatial memory deficits. Regul Pept 2001 102 : 147 156.
10. Olson ML, Olson EA, Qualls JH, Stratton JJ, Harding JW, Wright JW. Norleucine1-angiotensin IV alleviates mecamylamine-induced spatial memory deficits. Peptides 2004 25 : 233 241.
11. Albiston AL, Pederson ES, Burns P, Purcell B, Wright JW, Harding JW, Mendelsohn FA, Weisinger RS, Chai SY. Attenuation of scopolamine-induced learning deficits by LVV-hemorphin-7 in rats in the passive avoidance and water maze paradigms. Behav Brain Res 2004 154 : 239 243.
12. Stragier B, Clinckers R, Meurs A, De Bundel D, Sarre S, Ebinger G, Michotte Y, Smolders I. Involvement of the somatostatin-2 receptor in the anticonvulsant effect of angiotensin IV against pilocarpine-induced limbic seizures in rats. J Neurochem 2006 98 : 1100 1113.
13. Tchekalarova J, Kambourova T, Georgiev V. Effects of angiotensin III and angiotensin IV on pentylenetetrazol seizure susceptibility (threshold and kindling): Interaction with adenosine A(1) receptors. Brain Res Bull 2001 56 : 87 91.
14. Tchekalarova J, Sotiriou E, Angelatou F. Down-regulation of dopamine D1 and D2 receptors in the basal ganglia of PTZ kindling model of epilepsy: effects of angiotensin IV. Brain Res 2004 1024 : 159 166.
15. Swanson GN, Hanesworth JM, Sardinia MF, Coleman JK, Wright JW, Hall KL, Miller-Wing AV, Stobb JW, Cook VI, Harding EC, et al. Discovery of a distinct binding site for angiotensin II (3-8), a putative angiotensin IV receptor. Regul Pept 1992 40 : 409 419.
16. Harding JW, Cook VI, Miller-Wing AV, Hanesworth JM, Sardinia MF, Hall KL, Stobb JW, Swanson GN, Coleman JK, Wright JW, et al. Identification of an AII(3-8) [AIV] binding site in guinea pig hippocampus. Brain Res 1992 583 : 340 343.
17. Wright JW, Bechtholt AJ, Chambers SL, Harding JW. Angiotensin III and IV activation of the brain AT1 receptor subtype in cardiovascular function. Peptides 1996 17 : 1365 1371.
18. Lochard N, Thibault G, Silversides DW, Touyz RM, Reudelhuber TL. Chronic production of angiotensin IV in the brain leads to hypertension that is reversible with an angiotensin II AT1 receptor antagonist. Circ Res 2004 94 : 1451 1457.
19. Albiston AL, McDowall SG, Matsacos D, Sim P, Clune E, Mustafa T, Lee J, Mendelsohn FA, Simpson RJ, Connolly LM, et al. Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase. J Biol Chem 2001 276 : 48623 48626.
20. Speth RC, Karamyan VT. The significance of brain aminopeptidases in the regulation of the actions of angiotensin peptides in the brain. Heart Fail Rev 2008 13 : 299 309.
21. Karamyan VT, Speth RC. Enzymatic pathways of the brain renin-angiotensin system: Unsolved problems and continuing challenges. Regul Pept 2007 143 : 15 27.
22. Johnston CI. ACE inhibitors and the kidney. Nephron 1990 55 (Suppl 1 1 2.
23. Speth RC, Karamyan VT. Brain angiotensin receptors and binding proteins. Naunyn Schmiedebergs Arch Pharmacol 2008 377 : 283 293.
24. Araujo RC, Lima MP, Lomez ES, Bader M, Pesquero JB, Sumitani M, Pesquero JL. Tonin expression in the rat brain and tonin-mediated central production of angiotensin II. Physiol Behav 2002 76 : 327 333.
25. Reaux A, Fournie-Zaluski MC, Llorens-Cortes C. Angiotensin III: A central regulator of vasopressin release and blood pressure. Trends Endocrinol Metab 2001 12 : 157 162.
26. Reaux A, Fournie-Zaluski MC, David C, Zini S, Roques BP, Corvol P, Llorens-Cortes C. Aminopeptidase A inhibitors as potential central antihypertensive agents. Proc Natl Acad Sci U S A 1999 96 : 13415 13420.
27. Reaux A, de Mota N, Zini S, Cadel S, Fournie-Zaluski MC, Roques BP, Corvol P, Llorens-Cortes C. PC18, a specific aminopeptidase N inhibitor, induces vasopressin release by increasing the half-life of brain angiotensin III. Neuroendocrinology 1999 69 : 370 376.
28. Wilk S, Wilk E, Magnusson RP. Purification, characterization, and cloning of a cytosolic aspartyl aminopeptidase. J Biol Chem 1998 273 : 15961 15970.
29. Hwang SR, O'Neill A, Bark S, Foulon T, Hook V. Secretory vesicle aminopeptidase B related to neuropeptide processing: Molecular identification and subcellular localization to enkephalin- and NPY-containing chromaffin granules. J Neurochem 2007 100 : 1340 1350.
30. Chansel D, Czekalski S, Vandermeersch S, Ruffet E, Fournie-Zaluski MC, Ardaillou R. Characterization of angiotensin IV-degrading enzymes and receptors on rat mesangial cells. Am J Physiol 1998 275 : F535 F542.
31. Kokje RJ, Wilson WL, Brown TE, Karamyan VT, Wright JW, Speth RC. Central pressor actions of aminopeptidase-resistant angiotensin II analogs: Challenging the angiotensin III hypothesis. Hypertension 2007 49 : 1328 1335.
32. Mitsui T, Nomura S, Okada M, Ohno Y, Kobayashi H, Nakashima Y, Murata Y, Takeuchi M, Kuno N, Nagasaka T, et al. Hypertension and angiotensin II hypersensitivity in aminopeptidase A-deficient mice. Mol Med 2003 9 : 57 62.
33. McKinley MJ, Albiston AL, Allen AM, Mathai ML, May CN, McAllen RM, Oldfield BJ, Mendelsohn FA, Chai SY. The brain renin-angiotensin system: Location and physiological roles. Int J Biochem Cell Biol 2003 35 : 901 918.
34. Sakai K, Chapleau MW, Morimoto S, Cassell MD, Sigmund CD. Differential modulation of baroreflex control of heart rate by neuron- versus glia-derived angiotensin II. Physioll Genomics 2004 20 : 66 72.
35. Sernia C. Location and secretion of brain angiotensinogen. Regul Pept 1995 57 : 1 18.
36. Tham M, Sim MK, Tang FR. Location of renin-angiotensin system components in the hypoglossal nucleus of the rat. Regul Pept 2001 101 : 51 57.
37. Sherrod M, Davis DR, Zhou X, Cassell MD, Sigmund CD. Glial-specific ablation of angiotensinogen lowers arterial pressure in renin and angiotensinogen transgenic mice. Am J Physiol 2005 289 : R1763 R1769.
38. Slater EE, Defendini R, Zimmerman EA. Wide distribution of immunoreactive renin in nerve cells of human brain. Proc Natl Acad Sci U S A 1980 77 : 5458 5460.
39. Fischer-Ferraro C, Nahmod VE, Goldstein DJ, Finkielman S. Angiotensin and renin in rat and dog brain J Exp Med 1971 133 : 353 361.
40. Paul M, Wagner D, Metzger R, Ganten D, Lang RE, Suzuki F, Murakami K, Burbach JH, Ludwig G. Quantification of renin mRNA in various mouse tissues by a novel solution hybridization assay. J Hypertens 1988 6 : 247 252.
41. Samani NJ, Swales JD, Brammar WJ. Expression of the renin gene in extra-renal tissues of the rat. Biochem J 1988 253 : 907 910.
42. Lavoie JL, Cassell MD, Gross KW, Sigmund CD. Localization of renin expressing cells in the brain, by use of a REN-eGFP transgenic model. Physiol Genomics 2004 16 : 240 246.
43. Lavoie JL, Liu X, Bianco RA, Beltz TG, Johnson AK, Sigmund CD. Evidence supporting a functional role for intracellular renin in the brain. Hypertension 2006 47 : 461 466.
44. Saavedra JM, Correa FM, Seltzer A, Pinto JE, Viglione P, Tsutsumi K. Enhanced angiotensin converting enzyme binding in arteries from spontaneously hypertensive rats. J Hypertens 1992 10 : 1353 1359.
45. Barnes K, Turner AJ, Kenny AJ. Membrane localization of endopeptidase-24.11 and peptidyl dipeptidase A (angiotensin converting enzyme) in the pig brain: A study using subcellular fractionation and electron microscopic immunocytochemistry. J Neurochem 1992 58 : 2088 2096.
46. Thomas MA, Fleissner G, Stohr M, Hauptfleisch S, Lemmer B. Localization of components of the renin-angiotensin system in the suprachiasmatic nucleus of normotensive Sprague-Dawley rats: Part B. Angiotensin II (AT1)-receptors, a light and electron microscopic study. Brain Res 2004 1008 : 224 235.
47. Thomas MA, Fleissner G, Stohr M, Hauptfleisch S, Lemmer B. Localization of components of the renin-angiotensin system in the suprachiasmatic nucleus of normotensive Sprague-Dawley rats: Part A. Angiotensin I/II, a light and electron microscopic study. Brain Res 2004 1008 : 212 223.
48. Song L, Wilk E, Wilk S, Healy DP. Localization of immunoreactive glutamyl aminopeptidase in rat brain. I Association with cerebral microvessels. Brain Res 1993 606 : 286 294.
49. Healy DP, Wilk S. Localization of immunoreactive glutamyl aminopeptidase in rat brain. II Distribution and correlation with angiotensin II. Brain Res 1993 606 : 295 303.
50. Kunz J, Krause D, Kremer M, Dermietzel R. The 140-kDa protein of blood-brain barrier-associated pericytes is identical to aminopeptidase N. J Neurochem 1994 62 : 2375 2386.
51. Naveri L, Stromberg C, Saavedra JM. Angiotensin IV reverses the acute cerebral blood flow reduction after experimental subarachnoid hemorrhage in the rat. J Cereb Blood Flow Metab 1994 14 : 1096 1099.
52. Kramar EA, Krishnan R, Harding JW, Wright JW. Role of nitric oxide in angiotensin IV-induced increases in cerebral blood flow. Regul Pept 1998 74 : 185 192.
53. Kramar EA, Harding JW, Wright JW. Angiotensin II- and IV-induced changes in cerebral blood flow. Roles of AT1, AT2, and AT4 receptor subtypes. Regul Pept 1997 68 : 131 138.
54. Lanckmans K, Stragier B, Sarre S, Smolders I, Michotte Y. Nano-LC-MS/MS for the monitoring of angiotensin IV in rat brain microdialysates: Limitations and possibilities. J Sep Sci 2007 30 : 2217 2224.
55. Lanckmans K, Sarre S, Smolders I, Michotte Y. Use of a structural analogue versus a stable isotope labeled internal standard for the quantification of angiotensin IV in rat brain dialysates using nano-liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2007 21 : 1187 1195.
56. Hanesworth JM, Sardinia MF, Krebs LT, Hall KL, Harding JW. Elucidation of a specific binding site for angiotensin II(3-8), angiotensin IV, in mammalian heart membranes. J Pharmacol Exp Ther 1993 266 : 1036 1042.
57. Miller-Wing AV, Hanesworth JM, Sardinia MF, Hall KL, Wright JW, Speth RC, Grove KL, Harding JW. Central angiotensin IV binding sites: Distribution and specificity in guinea pig brain. J Pharmacol Exp Ther 1993 266 : 1718 1726.
58. von Bohlen und Halbach O, Albrecht D. Identification of angiotensin IV binding sites in the mouse brain by a fluorescent binding study. Neuroendocrinology 2000 72 : 218 223.
59. Chai SY, Bastias MA, Clune EF, Matsacos DJ, Mustafa T, Lee JH, McDowall SG, Paxinos G, Mendelsohn FA, Albiston AL. Distribution of angiotensin IV binding sites (AT4 receptor) in the human forebrain, midbrain and pons as visualised by in vitro receptor autoradiography. J Chem Neuroanat 2000 20 : 339 348.
60. Moeller I, Paxinos G, Mendelsohn FA, Aldred GP, Casley D, Chai SY. Distribution of AT4 receptors in the Macaca fascicularis brain. Brain Res 1996 712 : 307 324.
61. Roberts KA, Krebs LT, Kramar EA, Shaffer MJ, Harding JW, Wright JW. Autoradiographic identification of brain angiotensin IV binding sites and differential c-Fos expression following intracerebroventricular injection of angiotensin II and IV in rats. Brain Res 1995 682 : 13 21.
62. Sardinia MF, Hanesworth JM, Krebs LT, Harding JW. AT4 receptor binding characteristics: D-amino acid- and glycine-substituted peptides. Peptides 1993 14 : 949 954.
63. Sardinia MF, Hanesworth JM, Krishnan F, Harding JW. AT4 receptor structure-binding relationship: N-terminal-modified angiotensin IV analogues. Peptides 1994 15 : 1399 1406.
64. Krishnan R, Hanesworth JM, Wright JW, Harding JW. Structure-binding studies of the adrenal AT4 receptor: Analysis of position two- and three-modified angiotensin IV analogs. Peptides 1999 20 : 915 920.
65. Wright JW, Harding JW. Brain angiotensin receptor subtypes AT1, AT2, and AT4 and their functions. Regul Pept 1995 59 : 269 295.
66. Krebs LT, Kramar EA, Hanesworth JM, Sardinia MF, Ball AE, Wright JW, Harding JW. Characterization of the binding properties and physiological action of divalinal-angiotensin IV, a putative AT4 receptor antagonist. Regul Pept 1996 67 : 123 130.
67. Moeller I, Lew RA, Mendelsohn FA, Smith AI, Brennan ME, Tetaz TJ, Chai SY. The globin fragment LVV-hemorphin-7 is an endogenous ligand for the AT4 receptor in the brain. J Neurochem 1997 68 : 2530 2537.
68. Moeller I, Albiston AL, Lew RA, Mendelsohn FA, Chai SY. A globin fragment, LVV-hemorphin-7, induces [3H]thymidine incorporation in a neuronal cell line via the AT4 receptor. J Neurochem 1999 73 : 301 308.
69. Lee J, Chai SY, Mendelsohn FA, Morris MJ, Allen AM. Potentiation of cholinergic transmission in the rat hippocampus by angiotensin IV and LVV-hemorphin-7. Neuropharmacology 2001 40 : 618 623.
70. Lee J, Albiston AL, Allen AM, Mendelsohn FA, Ping SE, Barrett GL, Murphy M, Morris MJ, McDowall SG, Chai SY. Effect of I.C.V. injection of AT(4) receptor ligands, Nle(1)-angiotensin IV and LVV-hemorphin 7, on spatial learning in rats. Neuroscience 2004 124 : 341 349.
71. Stragier B, Sarre S, Vanderheyden P, Vauquelin G, Fournie-Zaluski MC, Ebinger G, Michotte Y. Metabolism of angiotensin II is required for its in vivo effect on dopamine release in the striatum of the rat. J Neurochem 2004 90 : 1251 1257.
72. Zhang JH, Stobb JW, Hanesworth JM, Sardinia MF, Harding JW. Characterization and purification of the bovine adrenal angiotensin IV receptor (AT4) using [125I]benzoylphenylalanine-angiotensin IV as a specific photolabel. J Pharmacol Exp Ther 1998 287 : 416 424.
73. Zhang JH, Hanesworth JM, Sardinia MF, Alt JA, Wright JW, Harding JW. Structural analysis of angiotensin IV receptor (AT4) from selected bovine tissues. J Pharmacol Exp Ther 1999 289 : 1075 1083.
74. Bernier SG, Bellemare JM, Escher E, Guillemette G. Characterization of AT4 receptor from bovine aortic endothelium with photosensitive analogues of angiotensin IV. Biochemistry 1998 37 : 4280 4287.
75. Mustafa T, Chai SY, Mendelsohn FA, Moeller I, Albiston AL. Characterization of the AT(4) receptor in a human neuroblastoma cell line (SK-N-MC). J Neurochem 2001 76 : 1679 1687.
76. Fernando RN, Larm J, Albiston AL, Chai SY. Distribution and cellular localization of insulin-regulated aminopeptidase in the rat central nervous system. J Comp Neurol 2005 487 : 372 390.
77. Kandror KV, Yu L, Pilch PF. The major protein of GLUT4-containing vesicles, gp160, has aminopeptidase activity. J Biol Chem 1994 269 : 30777 30780.
78. Keller SR, Scott HM, Mastick CC, Aebersold R, Lienhard GE. Cloning and characterization of a novel insulin-regulated membrane aminopeptidase from Glut4 vesicles. J Biol Chem 1995 270 : 23612 23618.
79. Ross SA, Scott HM, Morris NJ, Leung WY, Mao F, Lienhard GE, Keller SR. Characterization of the insulin-regulated membrane aminopeptidase in 3T3-L1 adipocytes. J Biol Chem 1996 271 : 3328 3332.
80. Rogi T, Tsujimoto M, Nakazato H, Mizutani S, Tomoda Y. Human placental leucine aminopeptidase/oxytocinase. A new member of type II membrane-spanning zinc metallopeptidase family. J Biol Chem 1996 271 : 56 61.
81. Matsumoto H, Nagasaka T, Hattori A, Rogi T, Tsuruoka N, Mizutani S, Tsujimoto M. Expression of placental leucine aminopeptidase/oxytocinase in neuronal cells and its action on neuronal peptides. Eur J Biochem 2001 268 : 3259 3266.
82. Matsumoto H, Rogi T, Yamashiro K, Kodama S, Tsuruoka N, Hattori A, Takio K, Mizutani S, Tsujimoto M. Characterization of a recombinant soluble form of human placental leucine aminopeptidase/oxytocinase expressed in Chinese hamster ovary cells. Eur J Biochem 2000 267 : 46 52.
83. Herbst JJ, Ross SA, Scott HM, Bobin SA, Morris NJ, Lienhard GE, Keller SR. Insulin stimulates cell surface aminopeptidase activity toward vasopressin in adipocytes. Am J Physiol 1997 272 : E600 E606.
84. Lew RA, Mustafa T, Ye S, McDowall SG, Chai SY, Albiston AL. Angiotensin AT4 ligands are potent, Competitive inhibitors of insulin regulated aminopeptidase (IRAP). J Neurochem 2003 86 : 344 350.
85. Wallis MG, Lankford MF, Keller SR. Vasopressin is a physiological substrate for the insulin-regulated aminopeptidase IRAP. Am J Physiol Endocrinol Metab 2007 293 : E1092 E1102.
86. Albiston AL, Peck GR, Yeatman HR, Fernando R, Ye S, Chai SY. Therapeutic targeting of insulin-regulated aminopeptidase: Heads and tails? Pharmacol Ther 2007 116 : 417 427.
87. Wright JW, Harding JW. Important role for angiotensin III and IV in the brain renin- angiotensin system. Brain Res Rev 1997 25 : 96 124.
88. von Bohlen und Halbach O, Albrecht D. Opposite effects of angiotensin II and IV in the lateral nucleus of the amygdala. Brain Res Bull 1998 47 : 311 315.
89. Handa RK, Harding JW, Simasko SM. Characterization and function of the bovine kidney epithelial angiotensin receptor subtype 4 using angiotensin IV and divalinal angiotensin IV as receptor ligands. J Pharmacol Exp Ther 1999 291 : 1242 1249.
90. Handa RK. Characterization and signaling of the AT(4) receptor in human proximal tubule epithelial (HK-2) cells. J Am Soc Nephrol 2001 12 : 440 449.
91. Dulin N, Madhun ZT, Chang CH, Berti-Mattera L, Dickens D, Douglas JG. Angiotensin IV receptors and signaling in opossum kidney cells. Am J Physiol 1995 269 : F644 F652.
92. Gesualdo L, Ranieri E, Monno R, Rossiello MR, Colucci M, Semeraro N, Grandaliano G, Schena FP, Ursi M, Cerullo G. Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells. Kidney Int 1999 56 : 461 470.
93. Esteban V, Ruperez M, Sanchez-Lopez E, Rodriguez-Vita J, Lorenzo O, Demaegdt H, Vanderheyden P, Egido J, Ruiz-Ortega M. Angiotensin IV activates the nuclear transcription factor-kappaB and related proinflammatory genes in vascular smooth muscle cells. Circ Res 2005 96 : 965 973.
94. Albrecht D, Broser M, Kruger H. Excitatory action of angiotensins II and IV on hippocampal neuronal activity in urethane anesthetized rats. Regul Pept 1997 70 : 105 109.
95. Kramar EA, Armstrong DL, Ikeda S, Wayner MJ, Harding JW, Wright JW. The effects of angiotensin IV analogs on long-term potentiation within the CA1 region of the hippocampus in vitro. Brain Res 2001 897 : 114 121.
96. Wayner MJ, Armstrong DL, Phelix CF, Wright JW, Harding JW. Angiotensin IV enhances LTP in rat dentate gyrus in vivo. Peptides 2001 22 : 1403 1414.
97. Davis CJ, Kramar EA, De A, Meighan PC, Simasko SM, Wright JW, Harding JW. AT4 receptor activation increases intracellular calcium influx and induces a non-N-methyl-D-aspartate dependent form of long-term potentiation. Neuroscience 2006 137 : 1369 1379.
98. Chai SY, Fernando R, Peck G, Ye SY, Mendelsohn FA, Jenkins TA, Albiston AL. The angiotensin IV/AT4 receptor. Cell Mol Life Sci 2004 61 : 2728 2737.
99. Stragier B, Demaegdt H, De Bundel D, Smolders I, Sarre S, Vauquelin G, Ebinger G, Michotte Y, Vanderheyden P. Involvement of insulin-regulated aminopeptidase and/or aminopeptidase N in the angiotensin IV-induced effect on dopamine release in the striatum of the rat. Brain Res 2007 1131 : 97 105.
100. Shipp MA, Look AT. Hematopoietic differentiation antigens that are membrane-associated enzymes: Cutting is the key! Blood 1993 82 : 1052 1070.
101. Santos AN, Langner J, Herrmann M, Riemann D. Aminopeptidase N/CD13 is directly linked to signal transduction pathways in monocytes. Cell Immunol 2000 201 : 22 32.
102. Mittrucker HW, Steeg C, Malissen B, Fleischer B. The cytoplasmic tail of the T cell receptor zeta chain is required for signaling via CD26. Eur J Immunol 1995 25 : 295 297.
103. Waters SB, D'Auria M, Martin SS, Nguyen C, Kozma LM, Luskey KL. The amino terminus of insulin-responsive aminopeptidase causes Glut4 translocation in 3T3-L1 adipocytes. J Biol Chem 1997 272 : 23323 23327.
104. Corvera S, Chawla A, Chakrabarti R, Joly M, Buxton J, Czech MP. A double leucine within the GLUT4 glucose transporter COOH-terminal domain functions as an endocytosis signal. J Cell Biol 1994 126 : 1625.
105. Garippa RJ, Johnson A, Park J, Petrush RL, McGraw TE. The carboxyl terminus of GLUT4 contains a serine-leucine-leucine sequence that functions as a potent internalization motif in Chinese hamster ovary cells. J Biol Chem 1996 271 : 20660 20668.
106. Subtil A, Lampson MA, Keller SR, McGraw TE. Characterization of the insulin-regulated endocytic recycling mechanism in 3T3-L1 adipocytes using a novel reporter molecule. J Biol Chem 2000 275 : 4787 4795.
107. Fernando RN, Luff SE, Albiston AL, Chai SY. Sub-cellular localization of insulin-regulated membrane aminopeptidase, Irap to vesicles in neurons. J Neurochem 2007 102 : 967 976.
108. El Messari S, Ait-Ikhlef A, Ambroise DH, Penicaud L, Arluison M. Expression of insulin-responsive glucose transporter GLUT4 mRNA in the rat brain and spinal cord: an in situ hybridization study. J Chem Neuroanat 2002 24 : 225 242.
109. El Messari S, Leloup C, Quignon M, Brisorgueil MJ, Penicaud L, Arluison M. Immunocytochemical localization of the insulin-responsive glucose transporter 4 (Glut4) in the rat central nervous system. J Comp Neurol 1998 399 : 492 512.
110. Gonzatti-Haces M, Seth A, Park M, Copeland T, Oroszlan S, Vande Woude GF. Characterization of the TPR-MET oncogene p65 and the MET protooncogene p140 protein-tyrosine kinases. Proc Natl Acad Sci U S A 1988 85 : 21 25.
111. Epstein AN, Fitzsimons JT, Rolls BJ. Drinking induced by injection of angiotensin into the rain of the rat. J Physiol 1970 210 : 457 474.
112. Buckley JP. The central effects of the renin-angiotensin system. Clin Exp Hypertens 1988 10 : 1 16.
113. Gohlke P, Weiss S, Jansen A, Wienen W, Stangier J, Rascher W, Culman J, Unger T. AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats. J Pharmacol Exp Ther 2001 298 : 62 70.
114. Li Z, Iwai M, Wu L, Shiuchi T, Jinno T, Cui TX, Horiuchi M. Role of AT2 receptor in the brain in regulation of blood pressure and water intake. Am J Physiol Heart Circ Physiol 2003 284 : H116 H121.
115. Fitzsimons JT. The effect on drinking of peptide precursors and of shorter chain peptide fragments of angiotensin II injected into the rat's diencephalon. J Physiol 1971 214 : 295 303.
116. Le MT, Vanderheyden PM, Szaszak M, Hunyady L, Vauquelin G. Angiotensin IV is a potent agonist for constitutive active human AT1 receptors. Distinct roles of the N-and C-terminal residues of angiotensin II during AT1 receptor activation. J Biol Chem 2002 277 : 23107 23110.
117. Ellis J, Warburton P, Donnelly D, Balmforth AJ. Conformational induction is the key process for activation of the AT1 receptor. Biochem Pharmacol 2006 71 : 464 471.
118. Pan HL. Brain angiotensin II and synaptic transmission. Neuroscientist 2004 10 : 422 431.
119. Haas HL, Felix D, Celio MR, Inagami T. Angiotensin II in the hippocampus. A histochemical and electrophysiological study. Experientia 1980 36 : 1394 1395.
120. Hadjiivanova CH, Georgiev V. In vitro effect of angiotensin II on GABA release in rat hippocampus. Neuropeptides 1998 32 : 431 434.
121. Wright JW, Kramar EA, Myers ED, Davis CJ, Harding JW. Ethanol-induced suppression of LTP can be attenuated with an angiotensin IV analog. Regul Pept 2003 113 : 49 56.
122. Armstrong DL, Garcia EA, Ma T, Quinones B, Wayner MJ. Angiotensin II blockade of long-term potentiation at the perforant path-granule cell synapse in vitro. Peptides 1996 17 : 689 693.
123. Bliss TV, Lomo T. Long-lasting potentiation of synaptic transmission in the dentate area of the anaesthetized rabbit following stimulation of the perforant path. J Physiol 1973 232 : 331 356.
124. Bliss TV, Collingridge GL. A synaptic model of memory: Long-term potentiation in the hippocampus. Nature 1993 361 : 31 39.
125. Royer S, Pare D. Conservation of total synaptic weight through balanced synaptic depression and potentiation. Nature 2003 422 : 518 522.
126. Meador KJ. The basic science of memory as it applies to epilepsy. Epilepsia 2007 48 (Suppl 9 23 25.
127. Albensi BC, Ata G, Schmidt E, Waterman JD, Janigro D. Activation of long-term synaptic plasticity causes suppression of epileptiform activity in rat hippocampal slices. Brain Res 2004 998 : 56 64.
128. Cain DP, Hargreaves EL, Boon F, Dennison Z. An examination of the relations between hippocampal long-term potentiation, Kindling, afterdischarge, and place learning in the water maze. Hippocampus 1993 3 : 153 163.
129. von Bohlen und Halbach O, Albrecht D. Angiotensin II inhibits long-term potentiation within the lateral nucleus of the amygdala through AT1 receptors. Peptides 1998 19 : 1031 1036.
130. Tchekalarova J, Albrecht D. Angiotensin II suppresses long-term depression in the lateral amygdala of mice via L-type calcium channels. Neurosci Lett 2007 415 : 68 72.
131. Malenka RC. The role of postsynaptic calcium in the induction of long-term potentiation. Mol Neurobiol 1991 5 : 289 295.
132. Freir DB, Herron CE. Inhibition of L-type voltage dependent calcium channels causes impairment of long-term potentiation in the hippocampal CA1 region in vivo. Brain Res 2003 967 : 27 36.
133. Moosmang S, Haider N, Klugbauer N, Adelsberger H, Langwieser N, Muller J, Stiess M, Marais E, Schulla V, Lacinova L, et al. Role of hippocampal Cav1.2 Ca2+ channels in NMDA receptor-independent synaptic plasticity and spatial memory. J Neurosci 2005 25 : 9883 9892.
134. Denny JB, Polan-Curtain J, Wayner MJ, Armstrong DL. Angiotensin II blocks hippocampal long-term potentiation. Brain Res 1991 567 : 321 324.
135. Wayner MJ, Armstrong DL, Polan-Curtain JL, Denny JB. Role of angiotensin II and AT1 receptors in hippocampal LTP. Pharmacol Biochem Behav 1993 45 : 455 464.
136. Wayner MJ, Polan-Curtain J, Armstrong DL. Dose and time dependency of angiotensin II inhibition of hippocampal long-term potentiation. Peptides 1995 16 : 1079 1082.
137. Harding JW, Erickson JB, Camara CC, Abhold RH, Wright JW. High-performance liquid chromatographic analysis of "specifically bound" label after [125I]angiotensin II binding to rat brain membranes. Neurosci Lett 1986 65 : 23 28.
138. Wayner MJ, Polan-Curtain J, Armstrong DL. Angiotensin AII AT1 receptor mediates ethanol-diazepam inhibition of hippocampal LTP. Chin J Physiol 1994 37 : 55 61.
139. Chepkova AN, French P, De Wied D, Ontskul AH, Ramakers GM, Skrebitski VG, Gispen WH, Urban IJ. Long-lasting enhancement of synaptic excitability of CA1/subiculum neurons of the rat ventral hippocampus by vasopressin and vasopressin(4-8). Brain Res 1995 701 : 255 266.
140. Dubrovsky B, Tatarinov A, Gijsbers K, Harris J, Tsiodras A. Effects of arginine-vasopressin (AVP) on long-term potentiation in intact anesthetized rats. Brain Res Bull 2003 59 : 467 472.
141. Sakurai E, Maeda T, Kaneko S, Akaike A, Satoh M. Inhibition by [Arg8]-vasopressin of long term potentiation in guinea pig hippocampal slice. Jpn J Pharmacol 1998 77 : 103 105.
142. Tomizawa K, Iga N, Lu YF, Moriwaki A, Matsushita M, Li ST, Miyamoto O, Itano T, Matsui H. Oxytocin improves long-lasting spatial memory during motherhood through MAP kinase cascade. Nat Neurosci 2003 6 : 384 390.
143. Dubrovsky B, Harris J, Gijsbers K, Tatarinov A. Oxytocin induces long-term depression on the rat dentate gyrus: Possible ATPase and ectoprotein kinase mediation. Brain Res Bull 2002 58 : 141 147.
144. Yasui M, Kawasaki K. CCKB-receptor activation augments the long-term potentiation in guinea pig hippocampal slices. Jpn J Pharmacol 1995 68 : 441 447.
145. Balschun D, Reymann KG. Cholecystokinin (CCK-8S) prolongs "unsaturated" theta-pulse induced long-term potentiation in rat hippocampal CA1 in vitro. Neuropeptides 1994 26 : 421 427.
146. Baratta MV, Lamp T, Tallent MK. Somatostatin depresses long-term potentiation and Ca2+ signaling in mouse dentate gyrus. J Neurophysiol 2002 88 : 3078 3086.
147. Wagner JJ, Terman GW, Chavkin C. Endogenous dynorphins inhibit excitatory neurotransmission and block LTP induction in the hippocampus. Nature 1993 363 : 451 454.
148. Dash PK, Orsi SA, Moore AN. Spatial memory formation and memory-enhancing effect of glucose involves activation of the tuberous sclerosis complex - mammalian target of rapamycin pathway. J Neurosci 2006 26 : 8048 8056.
149. Tang SJ, Reis G, Kang H, Gingras AC, Sonenberg N, Schuman EM. A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus. Proc Natl Acad Sci U S A 2002 99 : 467 472.
150. Lenz G, Avruch J. Glutamatergic regulation of the p70S6 kinase in primary mouse neurons. J Biol Chem 2005 280 : 38121 38124.
151. Vickers CA, Dickson KS, Wyllie DJ. Induction and maintenance of late-phase long-term potentiation in isolated dendrites of rat hippocampal CA1 pyramidal neurons. J Physiol 2005 568 : 803 813.
152. Tsokas P, Ma T, Iyengar R, Landau EM, Blitzer RD. Mitogen-activated protein kinase upregulates the dendritic translation machinery in long-term potentiation by controlling the mammalian target of rapamycin pathway. J Neurosci 2007 27 : 5885 5894.
153. Lu J, Zhang J, Block ER, Patel JM. Angiotensin IV enhances phosphorylation of 4EBP1 by multiple signaling events in lung endothelial cells. Mol Cell Biochem 2005 275 : 181 188.
154. Tyndall SJ, Walikonis RS. Signaling by hepatocyte growth factor in neurons is induced by pharmacological stimulation of synaptic activity. Synapse 2007 61 : 199 204.
155. Tyndall SJ, Patel SJ, Walikonis RS. Hepatocyte growth factor-induced enhancement of dendritic branching is blocked by inhibitors of N-methyl-D-aspartate receptors and calcium/calmodulin-dependent kinases. J Neurosci Res 2007 85 : 2343 2351.
156. Akimoto M, Baba A, Ikeda-Matsuo Y, Yamada MK, Itamura R, Nishiyama N, Ikegaya Y, Matsuki N. Hepatocyte growth factor as an enhancer of NMDA currents and synaptic plasticity in the hippocampus. Neuroscience 2004 128 : 155 162.
157. Whitlock Jr, Heynen AJ, Shuler MG, Bear MF. Learning induces long-term potentiation in the hippocampus. Science 2006 313 : 1093 1097.
158. Burgess N, Maguire EA, O'Keefe J. The human hippocampus and spatial and episodic memory. Neuron 2002 35 : 625 641.
159. Eichenbaum H. The long and winding road to memory consolidation. Nat Neurosci 2001 4 : 1057 1058.
160. Bast T. Toward an integrative perspective on hippocampal function: from the rapid encoding of experience to adaptive behavior. Rev Neurosci 2007 18 : 253 281.
161. Ono T, Nishijo H, Uwano T. Amygdala role in conditioned associative learning. Prog Neurobiol 1995 46 : 401 422.
162. Sigurdsson T, Doyere V, Cain CK, LeDoux JE. Long-term potentiation in the
163. Belcheva I, Chobanova M, Georgiev V. Differential behavioral effects of angiotensin II microinjected unilaterally into the CA1 hippocampal area. Regul Pept 1998 74 : 67 71.
164. Belcheva I, Georgiev V, Chobanova M, Hadjiivanova C. Behavioral effects of angiotensin II microinjected into CA1 hippocampal area. Neuropeptides 1997 31 : 60 64.
165. Kulakowska A, Karwowska W, Wisniewski K, Braszko JJ. Losartan influences behavioural effects of angiotensin II in rats. Pharmacol Res 1996 34 : 109 115.
166. Braszko JJ, Wisniewski K. Effect of angiotensin II and saralasin on motor activity and the passive avoidance behavior of rats. Peptides 1988 9 : 475 479.
167. Braszko JJ, Kulakowska A, Winnicka MM. Effects of angiotensin II and its receptor antagonists on motor activity and anxiety in rats. J Physiol Pharmacol 2003 54 : 271 281.
168. Braszko JJ, Kupryszewski G, Witczuk B, Wisniewski K. Angiotensin II-(3-8)-hexapeptide affects motor activity, performance of passive avoidance and a conditioned avoidance response in rats. Neuroscience 1988 27 : 777 783.
169. Braszko JJ. Involvement of D1 dopamine receptors in the cognitive effects of angiotensin IV and des-Phe6 angiotensin IV. Peptides 2004 25 : 1195 1203.
170. Braszko JJ, Walesiuk A, Wielgat P. Cognitive effects attributed to angiotensin II may result from its conversion to angiotensin IV. J Renin Angiotensin Aldosterone Syst 2006 7 : 168 174.
171. Braszko JJ, Wielgat P, Walesiuk A. Effect of D(3) dopamine receptors blockade on the cognitive effects of angiotensin IV in rats. Neuropeptides 2008 42 : 301 309.
172. Lee EH, Ma YL, Wayner MJ, Armstrong DL. Impaired retention by angiotensin II mediated by the AT1 receptor. Peptides 1995 16 : 1069 1071.
173. Kerr DS, Bevilaqua LR, Bonini JS, Rossato JI, Kohler CA, Medina JH, Izquierdo I, Cammarota M. Angiotensin II blocks memory consolidation through an AT2 receptor-dependent mechanism. Psychopharmacology (Berl) 2005 179 : 529 535.
174. Bonini JS, Bevilaqua LR, Zinn CG, Kerr DS, Medina JH, Izquierdo I, Cammarota M. Angiotensin II disrupts inhibitory avoidance memory retrieval. Horm Behav 2006 50 : 308 313.
175. Yonkov DI, Georgiev VP, Opitz MJ. Participation of angiotensin II in learning and memory. II Interactions of angiotensin II with dopaminergic drugs. Method Find Exp Clin Pharmacol 1986 8 : 203 206.
176. Georgiev VP, Yonkov DI, Kambourova TS. Interactions between angiotensin II and baclofen in shuttle-box and passive avoidance performance. Neuropeptides 1988 12 : 155 158.
177. Tchekalarova J, Kambourova T, Georgiev V. Interaction of angiotensin II and III with adenosine A(1) receptor-related drugs in passive avoidance conditioning in rats. Behav Brain Res 2002 129 : 61 64.
178. de Souza FA, Sanchis-Segura C, Fukada SY, de Bortoli VC, Zangrossi H Jr., de Oliveira AM. Intracerebroventricular effects of angiotensin II on a step-through passive avoidance task in rats. Neurobiol Learn Mem 2004 81 : 100 103.
179. Braszko JJ. Valsartan abolishes most of the memory-improving effects of intracerebroventricular angiotensin II in rats. Clin Exp Hypertens 2005 27 : 635 649.
180. Raghavendra V, Chopra K, Kulkarni SK. Comparative studies on the memory-enhancing actions of captopril and losartan in mice using inhibitory shock avoidance paradigm. Neuropeptides 2001 35 : 65 69.
181. Hirawa N, Uehara Y, Kawabata Y, Numabe A, Gomi T, Ikeda T, Suzuki T, Goto A, Toyo-oka T, Omata M. Long-term inhibition of renin-angiotensin system sustains memory function in aged Dahl rats. Hypertension 1999 34 : 496 502.
182. Tchekalarova J, Kambourova T, Georgiev V. Interaction between angiotensin IV and adenosine A(1) receptor related drugs in passive avoidance conditioning in rats. Behav Brain Res 2001 123 : 113 116.
183. Wright JW, Krebs LT, Stobb JW, Harding JW. The angiotensin IV system: Functional implications. Front Neuroendocrinol 1995 16 : 23 52.
184. Tsvetkov E, Carlezon WA, Benes FM, Kandel ER, Bolshakov VY. Fear conditioning occludes LTP-induced presynaptic enhancement of synaptic transmission in the cortical pathway to the lateral amygdala. Neuron 2002 34 : 289 300.
185. Belcheva I, Ternianov A, Georgiev V. Lateralized learning and memory effects of angiotensin II microinjected into the rat CA1 hippocampal area. Peptides 2000 21 : 407 411.
186. Baranowska D, Braszko JJ, Wisniewski K. Effect of angiotensin II and vasopressin on acquisition and extinction of conditioned avoidance in rats. Psychopharmacology (Berl) 1983 81 : 247 251.
187. Braszko JJ, Wisniewski K, Kupryszewski G, Witczuk B. Psychotropic effects of angiotensin II and III in rats: Locomotor and exploratory versus cognitive behaviour. Behav Brain Res 1987 25 : 195 203.
188. Braszko JJ. AT(2) but not AT(1) receptor antagonism abolishes angiotensin II increase of the acquisition of conditioned avoidance responses in rats. Behav Brain Res 2002 131 : 79 86.
189. Georgiev V, Yonkov D. Participation of angiotensin II in learning and memory. I Interaction of angiotensin II with saralasin. Method Find Exp Clin Pharmacol 1985 7 : 415 418.
190. Braszko JJ, Paslawski L, Karwowska-Polecka W, Holownia A. Trandolapril attenuates acquisition of conditioned avoidance in rats. Pol J Pharmacol 2000 52 : 195 201.
191. Braszko JJ. D2 dopamine receptor blockade prevents cognitive effects of Ang IV and des-Phe6 Ang IV. Physiol Behav 2006 88 : 152 191.
192. Braszko JJ, Kulakowska A, Winnicka MM, Karwowska-Polecka W. CGP 42112A abolishes facilitation of recognition caused by angiotensin II and angiotensin II(3-7) in rats. Acta Neurobiol Exp 1997 57 : 227 234.
193. Braszko J. The contribution of AT1 and AT2 angiotensin receptors to its cognitive effects. Acta Neurobiol Exp 1996 56 : 49 54.
194. Holy Z, Wisniewski K, Jachimowicz A, Braszko J. Behavioural activity of angiotensin II (3-7)4Phe - analogue of natural fragment 3-7 of angiotensin II. Rocz Akad Med Bialymst (1995) 1996 41 : 191 201.
195. Walther T, Voigt JP, Fukamizu A, Fink H, Bader M. Learning and anxiety in angiotensin-deficient mice. Behav Brain Res 1999 100 : 1 4.
196. Jenkins TA, Chai SY. Effect of chronic angiotensin converting enzyme inhibition on spatial memory and anxiety-like behaviours in rats. Neurobiol Learn Mem 2007 87 : 218 224.
197. Dennes RP, Barnes JC. Attenuation of scopolamine-induced spatial memory deficits in the rat by cholinomimetic and non-cholinomimetic drugs using a novel task in the 12-arm radial maze. Psychopharmacology (Berl) 1993 111 : 435 441.
198. Shepherd J, Bill DJ, Dourish CT, Grewal SS, McLenachan A, Stanhope KJ. Effects of the selective angiotensin II receptor antagonists losartan and PD123177 in animal models of anxiety and memory. Psychopharmacology (Berl) 1996 126 : 206 218.
199. Tracy HA Jr., Wayner MJ, Armstrong DL. Losartan improves the performance of ethanol-intoxicated rats in an eight-arm radial maze. Alcohol 1997 14 : 511 517.
200. Srinivasan J, Jayadev S, Kumaran D, Ahamed KF, Suresh B, Ramanathan M. Effect of losartan and enalapril on cognitive deficit caused by Goldblatt induced hypertension. Indian J Exp Biol 2005 43 : 241 246.
201. Amenta F, Mignini F, Rabbia F, Tomassoni D, Veglio F. Protective effect of anti-hypertensive treatment on cognitive function in essential hypertension: analysis of published clinical data. J Neurol Sci 2002 203-204 : 147 151.
202. Braszko JJ, Karwowska-Polecka W, Halicka D, Gard PR. Captopril and enalapril improve cognition and depressed mood in hypertensive patients. J Basic Clin Physiol Pharmacol 2003 14 : 323 343.
203. Chalmers J, MacMahon S. Perindopril pROtection aGainst REcurrent Stroke Study (PROGRESS): Interpretation and implementation. J Hypertens Suppl 2003 21 : S9 S14.
204. Fogari R, Mugellini A, Zoppi A, Marasi G, Pasotti C, Poletti L, Rinaldi A, Preti P. Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur J Clin Pharmacol 2004 59 : 863 868.
205. Fogari R, Mugellini A, Zoppi A, Derosa G, Pasotti C, Fogari E, Preti P. Influence of losartan and atenolol on memory function in very elderly hypertensive patients. J Hum Hypertens 2003 17 : 781 785.
206. Fogari R, Mugellini A, Zoppi A, Lazzari P, Destro M, Rinaldi A, Preti P. Effect of telmisartan/hydrochlorothiazide versus lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. J Hum Hypertens 2006 20 : 177 185.
207. Saxby BK, Harrington F, Wesnes KA, McKeith IG, Ford GA. Candesartan and cognitive decline in older patients with hypertension: A substudy of the SCOPE trial. Neurology 2008 70 : 1858 1866.
208. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens 2003 21 : 875 886.
209. Shibasaki Y, Mori Y, Tsutumi Y, Masaki H, Sakamoto K, Murasawa S, Maruyama K, Moriguchi Y, Tanaka Y, Iwasaka T, et al. Differential kinetics of circulating angiotensin IV and II after treatment with angiotensin II type 1 receptor antagonist and their plasma levels in patients with chronic renal failure. Clin Nephrol 1999 51 : 83 91.
210. McKinley MJ, Oldfield BJ. The brain as an endocrine target for peptide hormones. Trends Endocrinol Metab 1998 9 : 349 354.
211. Holownia A, Braszko JJ. Effect of angiotensin IV on the acquisition of the water maze task and ryanodine channel function. Pharmacol Biochem Behav 2003 76 : 85 91.
212. Ragozzino ME, Unick KE, Gold PE. Hippocampal acetylcholine release during memory testing in rats: Augmentation by glucose. Proc Natl Acad Sci U S A 1996 93 : 4693 4698.
213. Krebs DL, Parent MB. The enhancing effects of hippocampal infusions of glucose are not restricted to spatial working memory. Neurobiol Learn Mem 2005 83 : 168 172.
214. McNay EC, Fries TM, Gold PE. Decreases in rat extracellular hippocampal glucose concentration associated with cognitive demand during a spatial task. Proc Natl Acad Sci U S A 2000 97 : 2881 2885.
215. Matsumoto H, Hattori A, Mizutani S, Tsujimoto M. Cleavage of peptide hormones by placental leucine aminopeptidase/oxytocinase. In : Mizutani S, Turner AJ, Nomura S, Ino S, eds. Cell-surface aminopeptidases: Basic and clinical aspects. Amsterdam, Elsevier, 2001 : 295 299.
216. Bielsky IF, Young LJ. Oxytocin, vasopressin, and social recognition in mammals. Peptides 2004 25 : 1565 1574.
217. Bielsky IF, Hu SB, Ren X, Terwilliger EF, Young LJ. The V1a vasopressin receptor is necessary and sufficient for normal social recognition: A gene replacement study. Neuron 2005 47 : 503 513.
218. Alescio-Lautier B, Paban V, Soumireu-Mourat B. Neuromodulation of memory in the hippocampus by vasopressin. Eur J Pharmacol 2000 405 : 63 72.
219. Alescio-Lautier B, Soumireu-Mourat B. Role of vasopressin in learning and memory in the hippocampus. Prog Brain Res 1998 119 : 501 521.
220. Egashira N, Tanoue A, Higashihara F, Mishima K, Fukue Y, Takano Y, Tsujimoto G, Iwasaki K, Fujiwara M. V1a receptor knockout mice exhibit impairment of spatial memory in an eight-arm radial maze. Neurosci Lett 2004 356 : 195 198.
221. Engelmann M, Wotjak CT, Neumann I, Ludwig M, Landgraf R. Behavioral consequences of intracerebral vasopressin and oxytocin: Focus on learning and memory. Neurosci Biobehav Rev 1996 20 : 341 358.
222. Hiramatsu M, Inoue K, Kameyama T. Dynorphin A-(1-13) and (2-13) improve beta-amyloid peptide-induced amnesia in mice. Neuroreport 2000 11 : 431 435.
223. Hiramatsu M, Watanabe E. Dynorphin A (2-13) improves mecamylamine-induced learning impairment accompanied by reversal of reductions in acetylcholine release in rats. Neuropeptides 2006 40 : 47 56.
224. Ukai M, Shinkai N, Kameyama T. Involvement of dopamine receptors in beneficial effects of tachykinins on scopolamine-induced impairment of alternation performance in mice. Eur J Pharmacol 1998 350 : 39 45.
225. Ohno M, Kikusui M, Yoshimatsu A, Yamamoto T, Watanabe S. Somatostatin alleviates impairment of working memory induced by hippocampal muscarinic M1 receptor blockade in rats. Eur J Pharmacol 1994 271 : 557 560.
226. Lamirault L, Guillou JL, Micheau J, Jaffard R. Intrahippocampal injections of somatostatin dissociate acquisition from the flexible use of place responses. Eur J Neurosci 2001 14 : 567 570.
227. Sandin J, Nylander I, Georgieva J, Schott PA, Ogren SO, Terenius L. Hippocampal dynorphin B injections impair spatial learning in rats: A kappa-opioid receptor-mediated effect. Neuroscience 1998 85 : 375 382.
228. Date I, Takagi N, Takagi K, Kago T, Matsumoto K, Nakamura T, Takeo S. Hepatocyte growth factor improved learning and memory dysfunction of microsphere-embolized rats. J Neurosci Res 2004 78 : 442 453.
229. Date I, Takagi N, Takagi K, Kago T, Matsumoto K, Nakamura T, Takeo S. Hepatocyte growth factor attenuates cerebral ischemia-induced learning dysfunction. Biochem Biophys Res Commun 2004 319 : 1152 1158.
230. Takeuchi D, Sato N, Shimamura M, Kurinami H, Takeda S, Shinohara M, Suzuki S, Kojima M, Ogihara T, Morishita R. Alleviation of Abeta-induced cognitive impairment by ultrasound-mediated gene transfer of HGF in a mouse model. Gene Ther 2008 15 : 561 571.
231. Aroniadou-Anderjaska V, Fritsch B, Qashu F, Braga MF. Pathology and pathophysiology of the amygdala in epileptogenesis and epilepsy. Epilepsy Res 2008 78 : 102 116.
232. Dudek FE, Sutula TP. Epileptogenesis in the dentate gyrus: A critical perspective. Prog Brain Res 2007 163 : 755 773.
233. Bengzon J, Mohapel P, Ekdahl CT, Lindvall O. Neuronal apoptosis after brief and prolonged seizures. Prog Brain Res 2002 135 : 111 119.
234. Maru E, Kanda M, Ashida H. Functional and morphological changes in the hippocampal neuronal circuits associated with epileptic seizures. Epilepsia 2002 43 (Suppl 9 44 49.
235. McIntyre DC, Gilby KL. Parahippocampal networks, intractability, and the chronic epilepsy of kindling. Adv Neurol 2006 97 : 77 83.
236. Albensi BC, Oliver DR, Toupin J, Odero G. Electrical stimulation protocols for hippocampal synaptic plasticity and neuronal hyper-excitability: Are they effective or relevant? Exp Neurol 2007 204 : 1 13.
237. Wasterlain CG, Farber DB, Fairchild MD. Synaptic mechanisms in the kindled epileptic focus: A speculative synthesis. Adv Neurol 1986 44 : 411 433.
238. Georgiev VP, Lazarova MB, Kambourova TS. Interactions between angiotensin II, diazepam, clonazepam and di-n-propylacetate in pentylenetetrazol kindling seizures in mice. Neuropeptides 1991 18 : 187 191.
239. Georgiev VP, Lazarova MB, Kambourova TS. Effects of non-peptide angiotensin II-receptor antagonists on pentylenetetrazol kindling in mice. Neuropeptides 1996 30 : 401 404.
240. Tchekalarova J, Pechlivanova D, Kambourova T, Matsoukas J, Georgiev V. The effects of sarmesin, an angiotensin II analogue on seizure susceptibility, memory retention and nociception. Regul Pept 2003 111 : 191 197.
241. Georgiev V, Gyorgy L, Yonkov D, Getova D, Markovska V, Petkova B. Dopaminergic influence on the effects of angiotensin II in behavioural reactions. Physiol Bohemoslov 1985 34 : 45 48.
242. Georgiev VP, Lazarova MB, Petkov VD, Kambourova TS. Interactions between angiotensin II, GABA and diazepam in convulsive seizures. Neuropeptides 1986 7 : 329 336.
243. Georgiev V, Petkova B, Kambourova T. Adaptive changes in the effects of angiotensin II on the convulsive-seizure threshold in cases of altered sensitivity of dopamine receptors. Method Find Exp Clin Pharmacol 1988 10 : 295 299.
244. Tchekalarova J, Georgiev V. Adenosine-angiotensin II interactions in pentylenetetrazol seizure threshold in mice. J Physiol 1999 93 : 191 197.
245. Tchekalarova J, Georgiev V. Ang II and Ang III modulate PTZ seizure threshold in non-stressed and stressed mice: possible involvement of noradrenergic mechanism. Neuropeptides 2006 40 : 339 348.
246. Arganaraz GA, Konno AC, Perosa SR, Santiago JF, Boim MA, Vidotti DB, Varella PP, Costa LG, Canzian M, Porcionatto MA, et al. The renin-angiotensin system is upregulated in the cortex and hippocampus of patients with temporal lobe epilepsy related to mesial temporal sclerosis. Epilepsia 2008 49 : 1348 1357.
247. Tchekalarova J, Georgiev V. Angiotensin peptides modulatory system: How is it implicated in the control of seizure susceptibility? Life Sci 2005 76 : 955 970.
248. Boison D. Adenosine-based cell therapy approaches for pharmacoresistant epilepsies. Neurodegener Dis 2007 4 : 28 33.
249. Smolders I, Clinckers R, Meurs A, De Bundel D, Portelli J, Ebinger G, Michotte Y. Direct enhancement of hippocampal dopamine or serotonin levels as a pharmacodynamic measure of combined antidepressant-anticonvulsant action. Neuropharmacology 2008 54 : 1017 1028.
250. Bagdy G, Kecskemeti V, Riba P, Jakus R. Serotonin and epilepsy. J Neurochem 2007 100 : 857 873.
251. Georgiev VP, Lazarova MB, Kambourova TS. Further evidence for the interactions between angiotensin II and GABAergic transmission in pentylenetetrazol kindling seizures in mice. Neuropeptides 1995 28 : 29 34.
252. Clinckers R, Gheuens S, Smolders I, Meurs A, Ebinger G, Michotte Y. In vivo modulatory action of extracellular glutamate on the anticonvulsant effects of hippocampal dopamine and serotonin. Epilepsia 2005 46 : 828 836.
253. Clinckers R, Smolders I, Meurs A, Ebinger G, Michotte Y. Anticonvulsant action of hippocampal dopamine and serotonin is independently mediated by D and 5-HT receptors. J Neurochem 2004 89 : 834 843.
254. Binaschi A, Bregola G, Simonato M. On the role of somatostatin in seizure control: Clues from the hippocampus. Rev Neurosci 2003 14 : 285 301.
255. Buckmaster PS, Otero-Corchon V, Rubinstein M, Low MJ. Heightened seizure severity in somatostatin knockout mice. Epilepsy Res 2002 48 : 43 56.
256. Vezzani A, Hoyer D. Brain somatostatin: A candidate inhibitory role in seizures and epileptogenesis. Eur J Neurosci 1999 11 : 3767 3776.
257. Tallent MK, Qiu C. Somatostatin: An endogenous antiepileptic. Mol Cell Endocrinol 2007 286 : 96 103.
258. Loacker S, Sayyah M, Wittmann W, Herzog H, Schwarzer C. Endogenous dynorphin in epileptogenesis and epilepsy: Anticonvulsant net effect via kappa opioid receptors. Brain 2007 130 : 1017 1028.
259. Liu H, Cao Y, Basbaum AI, Mazarati AM, Sankar R, Wasterlain CG. Resistance to excitotoxin-induced seizures and neuronal death in mice lacking the preprotachykinin A gene. Proc Natl Acad Sci U S A 1999 96 : 12096 12101.
260. Theodore WH, Kelley K, Toczek MT, Gaillard WD. Epilepsy duration, febrile seizures, and cerebral glucose metabolism. Epilepsia 2004 45 : 276 279.
261. Matheja P, Weckesser M, Debus O, Lottgen J, Schuierer G, Schober O, Kurlemann G. Drug-induced changes in cerebral glucose consumption in bifrontal epilepsy. Epilepsia 2000 41 : 588 593.
262. Klepper J, Leiendecker B. GLUT1 deficiency syndrome-2007 update. Dev Med Child Neurol 2007 49 : 707 716.
263. Seidner G, Alvarez MG, Yeh JI, O'Driscoll KR, Klepper J, Stump TS, Wang D, Spinner NB, Birnbaum MJ, De Vivo DC. GLUT-1 deficiency syndrome caused by haploinsufficiency of the blood-brain barrier hexose carrier. Nat Genet 1998 18 : 188 191.
264. Garriga-Canut M, Schoenike B, Qazi R, Bergendahl K, Daley TJ, Pfender RM, Morrison JF, Ockuly J, Stafstrom C, Sutula T, et al. 2-deoxy-D-glucose reduces epilepsy progression by NRSF-CtBP-dependent metabolic regulation of chromatin structure. Nat Neurosci 2006 9 : 1382 1387.
265. Levitt P. Disruption of interneuron development. Epilepsia 2005 46 (Suppl 7 22 28.
266. Powell EM, Campbell DB, Stanwood GD, Davis C, Noebels JL, Levitt P. Genetic disruption of cortical interneuron development causes region- and GABA cell type-specific deficits, epilepsy, and behavioral dysfunction. J Neurosci 2003 23 : 622 631.
267. Waldstein SR, Manuck SB, Ryan CM, Muldoon MF. Neuropsychological correlates of hypertension: Review and methodologic considerations. Psychol Bull 1991 110 : 451 468.